Article Information
History
- December 2, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Alison Cutts1,*,
- Hillary Savoie2,
- Michael F. Hammer3,
- John Schreiber4,
- Celene Grayson1,
- Constanza Luzon1,
- Noam Butterfield1,
- Simon N. Pimstone1,
- Ernesto Aycardi1,
- Cynthia Harden1,
- Chuck Yonan5,
- Eric Jen5,
- Trung Nguyen5,
- Tara Carmack5 and
- Dietrich Haubenberger5
- 1Xenon Pharmaceuticals Inc., Burnaby, BC, Canada
- 2The Cute Syndrome Foundation, Troy, NY, USA
- 3Shay Emma Hammer Research Foundation and University of Arizona, Tucson, AZ, USA
- 4Children’s National Hospital, Washington DC, USA
- 5Neurocrine Biosciences, Inc., San Diego, CA, USA
- ↵*Corresponding Author:
Alison Cutts, Ph.D., Xenon Pharmaceuticals, 3650 Gilmore Way, Burnaby BC V4G 4W8, acutts{at}xenon-pharma.com
Posted December 02, 2021.
Clinical Characteristics and Treatment Experience of Individuals with SCN8A Developmental and Epileptic Encephalopathy (SCN8A-DEE): Findings from an Online Caregiver Survey
